These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20606064)

  • 21. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.
    Fung-Tomc J; Huczko E; Pearce M; Kessler RE
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1443-5. PubMed ID: 3143306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
    Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective survey of beta-lactamases produced by ceftazidime- resistant Pseudomonas aeruginosa isolated in a French hospital in 2000.
    De Champs C; Poirel L; Bonnet R; Sirot D; Chanal C; Sirot J; Nordmann P
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3031-4. PubMed ID: 12183264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
    Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chlorhexidine leads to the evolution of antibiotic-resistant Pseudomonas aeruginosa.
    Tag ElDein MA; Yassin AS; El-Tayeb O; Kashef MT
    Eur J Clin Microbiol Infect Dis; 2021 Nov; 40(11):2349-2361. PubMed ID: 34169445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
    J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
    Fung-Tomc J; Dougherty TJ; DeOrio FJ; Simich-Jacobson V; Kessler RE
    Antimicrob Agents Chemother; 1989 Apr; 33(4):498-502. PubMed ID: 2499250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
    J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
    Hocquet D; Nordmann P; El Garch F; Cabanne L; Plésiat P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.
    Peña C; Suarez C; Tubau F; Juan C; Moya B; Dominguez MA; Oliver A; Pujol M; Ariza J
    J Clin Microbiol; 2009 Aug; 47(8):2381-7. PubMed ID: 19494059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel genes responsible for overexpression of ampC in Pseudomonas aeruginosa PAO1.
    Tsutsumi Y; Tomita H; Tanimoto K
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5987-93. PubMed ID: 24041903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
    Wolter DJ; Schmidtke AJ; Hanson ND; Lister PD
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2997-3000. PubMed ID: 17517839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
    Bantar C; Di Chiara M; Nicola F; Relloso S; Smayevsky J
    Diagn Microbiol Infect Dis; 2000 May; 37(1):41-4. PubMed ID: 10794939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.
    Shields RK; Iovleva A; Kline EG; Kawai A; McElheny CL; Doi Y
    Clin Infect Dis; 2020 Dec; 71(10):2713-2716. PubMed ID: 32236408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
    Queenan AM; Shang W; Kania M; Page MG; Bush K
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3089-95. PubMed ID: 17591851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.
    Livermore DM; Mushtaq S; Doumith M; Jamrozy D; Nichols WW; Woodford N
    J Antimicrob Chemother; 2018 Dec; 73(12):3336-3345. PubMed ID: 30247546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.